INOVIQ Ltd (ASX:IIQ)

Market Cap	47.86M +15.9%
Revenue (ttm)	2.10M +24.5%
Net Income	-7.24M
EPS	-0.06
Shares Out	140.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,684
Open	0.3350
Previous Close	0.3400
Day's Range	0.3350 - 0.3400
52-Week Range	0.3120 - 0.5150
Beta	1.67
Analysts	Buy
Price Target	2.13 (+526.47%)
Earnings Date	Aug 26, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IIQ

Financial Performance

In fiscal year 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.